Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opportunities to Optimize Cancer Policies Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Mar
11
Today In Oncology
Stanford Names Leader for Drug Development and Precision Oncology
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks
FDA Releases Updated Guidance on Biosimilar Development
SABCS 2025: High-Level Review of Select Data
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo